Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide

Summary

Type 2N von Willebrand disease (VWD) is characterized by a markedly decreased affinity of von Willebrand factor (VWF) for factorVIII (FVIII) and is caused by mutations in the D’ or D3 domain of mature VWF. We now report a French patient with an atypical 2N VWD phenotype associating FVIII deficiency with plasmaVWF unable to bind FVIII (undetectableVWF:FVIIIB) but with an abnormal multimeric profile. This patient is heterozygous for both the frequent R854Q type 2NVWD mutation and a novel R763G mutation at the cleavage site betweenVWF propeptide and mature VWF. Four children of the patient displayed moderately decreased VWF:FVIIIB of plasma VWF and were heterozygous for either the R763G or the R854Q mutation. Children with the R763G mutation displayed the same abnormal multimeric profile as their father. Recombinant VWF (rVWF) expression studies performed in COS-7 cells showed that the R763G mutation subtly affects its multimeric profile and dramatically impairs its FVIII binding function. Furthermore, the characteristics of hybrid G763/Q854 rVWF resulting from cotransfection experiments were in agreement with the type 2N VWD diagnosis of the patient. We conclude that R763G is a new type 2N VWD mutation located in the VWF propeptide which alters the proteolytic processing of VWF and consequently its binding to FVIII.

Keywords

von Willebrand factor - von Willebrand disease - mutation - cleavage site

• References

• 1 Sadler JE. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
• 2 Verweij CL, Diergaarde PJ, Hart M. et al. Fulllength von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J 1986; 05: 1839-47.
• 3 Misumi Y, Oda K, Fujiwara T. et al. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 1991; 266: 16594-601.
• 4 Rehemtulla A, Kaufman RJ. Preferred sequence requirements for cleavage of pro-von Willebrand factor by propeptide-processing enzymes. Blood 1992; 79: 2349-55.
• 5 Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 06: 217-22.
• 6 Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ions. Proc Natl Acad Sci USA 1996; 87: 6306-10.
• 7 Mazurier C, Goudemand J, Hilbert L. et al. Type 2N von Willebrand disease: clinical manifestations, pathophysiology, laboratory diagnosis and molecular biology. Best Pract Res Clin Haematol 2001; 14 (02) 337-47.
• 8 Foster PA, Fulcher CA, Marti T. et al. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987; 262: 8443-6.
• 9 Mazurier C, Hilbert L. Type 2N von Willebrand Disease. Current Hematology Reports 2005; 04: 350-8.
• 10 Hilbert L, Gaucher C, de Romeuf C. et al. Leu697→Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994; 83: 1542-50.
• 11 Jorieux S, Fressinaud E, Goudemand J. et al. and the INSERM Network on Molecular Abnormalities in von Willebrand disease. Conformational changes in the D’ domain of von Willebrand factor induced by Cys 25 and Cys 95 mutations lead to factor VIII binding defect and multimeric impairment. Blood 2000; 95: 3139-45.
• 12 Ribba AS, Hilbert L, Lavergne JM. et al. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor. Blood 2000; 97: 952-9.
• 13 Mazurier C, Samor B, Goudemand M. Improved characterization of plasma von Willebrand factor heterogeneity when using 2.5% agarose gel electrophoresis. Thromb Haemost 1986; 55: 61-4.
• 14 Hilbert L, Gaucher C, Mazurier C. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased plateletdependent function of vWF. Blood 1995; 86: 1010-8.
• 15 Mazurier C, Parquet-Gernez A, Goudemand M. Dosage de l’antigène lié au Facteur VIII par la technique ELISA. Intérêt dans l’étude de la maladie de Willebrand. Pathol Biol (Paris) 1977; 25: 18.
• 16 Verweij C, Hart M, Pannekoek H. Proteolytic cleavage of the precursor of von Willebrand factor is not essential for multimer formation. J Biol Chem 1988; 263: 7921-4.
• 17 Wise RJ, Dorner AJ, Krane M. et al. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991; 266: 21948-55.
• 18 Journet AM, Saffaripour S, Cramer EM. et al. Von Willebrand factor storage requires intact prosequence cleavage site. European Journal of Cell Biology 1993; 60: 31-41.
• 19 Casonato A, Sartorello F, Cattini MG. et al. An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant. Blood 2003; 101: 151-6.